Identification of a transcriptionally inactive p53 mutant by functional analysis of separated alleles in yeasts (FASAY) in a child osteosarcoma tumor: A case report

被引:3
作者
Dekairelle, AF
Brichard, B
Delhez, H
Gala, JL
机构
[1] Univ Catholique Louvain, Ctr Human Genet, B-1200 Brussels, Belgium
[2] Clin Univ St Luc, Dept Pediat Hematol & Oncol, B-1200 Brussels, Belgium
[3] Queen Astrid Mil Hosp, Brussels, Belgium
关键词
FASAY; osteosarcoma; p53; prognosis;
D O I
10.1080/08880010490440455
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Tumor suppressor gene p53 is one of the most specific genetic alterations occurring in osteosarcoma pathogenesis. It is thought to be an early and key step in the tumorigenesis of osteosarcoma. However, whether the p53 status is a marker predictive of response to therapy and a marker of prognostic value remains controversial. The choice of p53 status detection method certainly account for discrepancies. The authors used a simple functional assay (functional analysis of separated allelles in yeast) on the tumor sample of an 8-year-old girl presenting with an osteosarcoma of the tibia. While making it possible to exclude the presence of a germline mutation, FASAY indicated the presence of a somatic p53 mutation lacking transcriptional activity on p21 and bax target genes. FASAY also strongly suggested a loss of heterozygosity p53 , which was confirmed by cytogenetic analysis. Sequencing of cDNA extracted from yeast colonies containing mutated p53 identified a 213 stop mutation in exon 6. Despite these p53 alterations, the child is still in complete remission after a follow-up of 48 months.
引用
收藏
页码:321 / 328
页数:8
相关论文
共 13 条
[1]
p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours [J].
Camplejohn, RS ;
Rutherford, J .
CELL PROLIFERATION, 2001, 34 (01) :1-14
[2]
Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast [J].
Flaman, JM ;
Robert, V ;
Lenglet, S ;
Moreau, V ;
Iggo, R ;
Frebourg, T .
ONCOGENE, 1998, 16 (10) :1369-1372
[3]
Gokgoz N, 2001, CANCER, V92, P2181, DOI 10.1002/1097-0142(20011015)92:8<2181::AID-CNCR1561>3.0.CO
[4]
2-3
[5]
HOGG A, 1992, ONCOGENE, V7, P1445
[6]
DETECTION OF LOSS OF HETEROZYGOSITY AT THE HUMAN TP53 LOCUS USING A DINUCLEOTIDE REPEAT POLYMORPHISM [J].
JONES, MH ;
NAKAMURA, Y .
GENES CHROMOSOMES & CANCER, 1992, 5 (01) :89-90
[7]
Molecular pathology and molecular pharmacology of osteosarcoma [J].
Ladanyi, M ;
Gorlick, R .
PEDIATRIC PATHOLOGY & MOLECULAR MEDICINE, 2000, 19 (05) :391-413
[8]
Evaluation of methods to detect p53 mutations in ovarian cancer [J].
Meinhold-Heerlein, I ;
Ninci, E ;
Ikenberg, H ;
Brandstetter, T ;
Ihling, C ;
Schwenk, I ;
Straub, A ;
Schmitt, B ;
Bettendorf, H ;
Iggo, R ;
Bauknecht, T .
ONCOLOGY, 2001, 60 (02) :176-188
[9]
The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma [J].
Park, YB ;
Kim, HS ;
Oh, JH ;
Lee, SH .
INTERNATIONAL ORTHOPAEDICS, 2001, 24 (06) :307-310
[10]
Slominski A, 1999, ARCH PATHOL LAB MED, V123, P1246